Discoveries in Medicine - Tackling the Side Effects of Gout Treatment
Vanderbilt University Medical Center Discover,
Adjunctive leflunomide may avoid the downside of methotrexate. For many gout patients with refractory disease following first-lin…
Horizon Therapeutics Reports Publication of Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA
Investing.com,
Horizon Therapeutics plc (Nasdaq: NASDAQ:) today announced the publication of the long-term data from the MIRROR randomized…
News story from Finanz Nachrichten on Thursday 06 July 2023
Finanz Nachrichten,
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
MarketScreener,
-- Month 12 data reinforce durable efficacy of co-treatment approach -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced…
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
Yahoo! Finance USA,
Month 12 data reinforce durable efficacy of co-treatment approach DUBLIN, July 06, 2023 Horizon Therapeutics plc (Nasdaq: HZNP…
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
Biospace,
-- Month 12 data reinforce durable efficacy of co-treatment approach -- DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasda…
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
PharmiWeb,
-- Month 12 data reinforce durable efficacy of co-treatment approach -- DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq…
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
MarketScreener,
-- Month 12 results from MIRROR randomized controlled trial to be featured on Nov.
News story from Finanz Nachrichten on Tuesday 08 November 2022
Finanz Nachrichten,
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
Morning Star,
-- Month 12 results from MIRROR randomized controlled trial to be featured on Nov.
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
Yahoo! Finance USA,
Month 12 results from MIRROR randomized controlled trial to be featured on Nov.
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
PharmiWeb,
-- Month 12 results from MIRROR randomized controlled trial to be featured on Nov.
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
Biospace,
-- Month 12 results from MIRROR randomized controlled trial to be featured on Nov.
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
Crwe World,
-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels…
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
Spoke,
DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that indicate KRYSTEXXA (pegloticase…
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
VB Profiles,
-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels…
Data Support the Use of KRYSTEXXA(TM) (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
Stockwatch,
-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels…
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
Benzinga,
-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels…
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
Yahoo!,
-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels…
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
Business Wire,
-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels…
Clinical Trial Evaluates PEG-MTX Therapy for Uncontrolled Gout
Doc Wire News,
When serum acid (sUA) levels continually remain above the solubility limit of 6.8 mg/dL, monosodium urate crystals (MSU…
News story from Finanz Nachrichten on Wednesday 14 September 2022
Finanz Nachrichten,
Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis
MarketScreener,
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of data from the MIRROR randomized controlled clinical…
Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis
Yahoo! Finance USA,
Month 6 data showed a greater than 30 percentage-point increase in efficacy, and a significant reduction in infusion reactions…
Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis
Business Wire,
-- Month 6 data showed a greater than 30 percentage-point increase in efficacy, and a significant reduction in infusion…
Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis
Biospace,
Sept. 14, 2022 12:00 UTC -- Month 6 data showed a greater than 30 percentage-point increase in efficacy, and a significant…
FDA Approves Krystexxa (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
Drugs.com,
Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to…
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
VB Profiles,
-- Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to…
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
Spoke,
-- Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to…
News story from Finanz Nachrichten on Friday 08 July 2022
Finanz Nachrichten,
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
MarketScreener,
-- Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to…
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
Yahoo! Finance USA,
Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to…
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
Business Wire,
-- Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to…
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
Biospace,
-- Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to…
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
PharmiWeb,
-- Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to…
Horizon Therapeutics plc Announces FDA Has Granted Priority Review of the Supplemental Biologics License Application (sBLA) for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living With Uncontrolled Gout
MarketScreener,
-- sBLA seeks to expand the label to include KRYSTEXXA plus methotrexate to help more patients achieve a complete and durable…
Horizon Therapeutics plc Announces FDA Has Granted Priority Review of the Supplemental Biologics License Application (sBLA) for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living With Uncontrolled Gout
Yahoo! Finance USA,
sBLA seeks to expand the label to include KRYSTEXXA plus methotrexate to help more patients achieve a complete and durable…
Horizon Therapeutics plc Announces FDA Has Granted Priority Review of the Supplemental Biologics License Application (sBLA) for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living With Uncontrolled Gout
Business Wire,
-- sBLA seeks to expand the label to include KRYSTEXXA plus methotrexate to help more patients achieve a complete and durable…
Horizon Therapeutics plc Announces FDA Has Granted Priority Review of the Supplemental Biologics License Application (sBLA) for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living With Uncontrolled Gout
Biospace,
-- sBLA seeks to expand the label to include KRYSTEXXA plus methotrexate to help more patients achieve a complete and durable…
News story from Finanz Nachrichten on Monday 10 January 2022
Finanz Nachrichten,
Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
DMN Newswire!,
— Submission based on recent results from the MIRROR randomized clinical trial, which showed a 71% response rate for patients…
Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
Spoke,
DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has submitted a supplemental…
Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
VB Profiles,
-- Submission based on recent results from the MIRROR randomized clinical trial, which showed a 71% response rate for patients…
Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
Crwe World,
Jan. 10, 2022 12:30 UTC -- Submission based on recent results from the MIRROR randomized clinical trial, which showed a 71…
Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
MarketScreener,
-- Submission based on recent results from the MIRROR randomized clinical trial, which showed a 71% response rate for patients…
Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
Yahoo! Finance USA,
Submission based on recent results from the MIRROR randomized clinical trial, which showed a 71% response rate for patients…
Horizon Therapeutics Plc Submits Supplemental Biologics License For The Concomitant Use Of KRYSTEXXA® (pegloticase Injection) Plus Methotrexate For People Living With Uncontrolled Gout
The Street,
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has submitted a supplemental Biologics License Application (sBLA…
Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
Morning Star,
-- Submission based on recent results from the MIRROR randomized clinical trial, which showed a 71% response rate for patients…
Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
Biospace,
-- Submission based on recent results from the MIRROR randomized clinical trial, which showed a 71% response rate for patients…
News story from Finanz Nachrichten on Monday 25 October 2021
Finanz Nachrichten,
MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Spoke,
-- Horizon expects to file a Supplemental Biologics License Application (sBLA) with the U.S.
MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Crwe World,
Oct. 25, 2021 12:00 UTC -- Horizon expects to file a Supplemental Biologics License Application (sBLA) with the U.S.
HORIZON THERAPEUTICS PUBLIC : MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
MarketScreener,
Horizon Therapeutics plc (Nasdaq: HZNP) today announced topline results met the primary endpoint, showing a significant…
MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Yahoo! Finance USA,
Horizon expects to file a Supplemental Biologics License Application (sBLA) with the U.S.
MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Biospace,
-- Horizon expects to file a Supplemental Biologics License Application (sBLA) with the U.S.
Clinician Q
Renal & Urology News,
Pegloticase, a recombinant form of uricase that converts insoluble uric acid to allantoin, which is more easily excreted by the…
Horizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat Uncontrolled Gout
Digital Journal,
DUBLIN--(Business Wire)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in…
News story from Finanz Nachrichten on Thursday 29 October 2020
Finanz Nachrichten,
Horizon Therapeutics plc : Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat Uncontrolled Gout
MarketScreener,
-- The AGILE trial is designed based on patient and clinician input and part of Horizon’s continued investment to impact the…
Horizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat Uncontrolled Gout
Business Wire,
-- The AGILE trial is designed based on patient and clinician input and part of Horizon’s continued investment to impact the…
Pegloticase in Combination With Methotrexate Improves Therapeutic Response in Uncontrolled Gout
Renal & Urology News,
Patients with uncontrolled gout may maintain a therapeutic response at 6 months with treatment with methotrexate (MTX) and…
Pegloticase plus methotrexate bested pegloticase alone in uncontrolled gout response
Healio.com,
2 min read Source/Disclosures Disclosures: Botson reports research support from Horizon Therapeutics and Radius Health, as well…
MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Digital Journal,
DUBLIN--(Business Wire)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the complete dataset on the…
MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate
One News Page,
( 7 minutes ago ) DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the…
MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate
One News Page,
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the complete dataset on the…
News story from Finanz Nachrichten on Wednesday 16 September 2020
Finanz Nachrichten,
MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate
DMN Newswire!,
— Data adds to growing body of evidence on immunomodulation with KRYSTEXXA and emerging approaches to reduce the impact of…
MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Business Wire,
-- Data adds to growing body of evidence on immunomodulation with KRYSTEXXA and emerging approaches to reduce the impact of…